Lung Cancer | Leveraging the Immune System for Therapeutic Benefit in Non-Small Cell Lung Cancer: Scientific Insights, Clinical Applications and Future Directions
Manage episode 235767422 series 1464173
Faculty presentations from a CME symposium held at the 2019 AACR Annual Meeting. Featuring perspectives from Drs Corey J Langer, Vali A Papadimitrakopoulou, Naiyer Rizvi and David R Spigel.
- Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Dr Langer (00:00)
- Incidence, Recognition and Management of Immune-Mediated and Other Toxicities with the Use of Anti-PD-1/PD-L1 Antibodies for Locally Advanced and Metastatic Disease — Dr Papadimitrakopoulou (11:08)
- Current Application of Immune Checkpoint Inhibitors in the Treatment of Metastatic NSCLC; Role for Patients with Actionable Tumor Mutations — Dr Spigel (22:52)
- Future Directions for Clinical and Translational Research — Dr Rizvi (34:22)